共 50 条
- [31] Impact of Significant Eosinophilia in Patients with Myelodysplastic Syndromes: Single Institution ExperienceBLOOD, 2017, 130Saadeh, Salwa S.Alkharabsheh, OmarZblewski, DarciPatnaik, Mrinal M.Gangat, NaseemaBegna, Kebede H.Alkhateeb, Hassan B.Elliott, Michelle A.He, RongPhuong NguyenHogan, William J.Litzow, Mark R.Al-Kali, Aref
- [32] Outcome of patients younger than 50 years old diagnosed with myelodysplastic syndromes (MDS): Single institution experience.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Al-Kali, ArefHe, RongPatnaik, MrinalHanna, KarenViswanatha, DavidGreipp, Patricia T.Zblewski, DarciElliott, Michelle A.Litzow, Mark RobertNguyen, Phuong L.
- [33] Hypomethylation agents in the treatment of myelodysplastic syndromes: Outpatient management of patients in community clinic. A single center experienceLEUKEMIA RESEARCH, 2013, 37 : S156 - S156Patel, K.Singh, A.Nandurkar, T.Lehman, S.Daji, A.Gor, A.Welsh, J.Naidu, S.Nathwani, N.Patel, A.
- [34] Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic SyndromesBLOOD, 2022, 140 : 1132 - 1134Mosquera Orgueira, AdrianPerez Encinas, ManuelDiaz Varela, Nicolas A.Mora, ElviraDiaz-Beya, MarinaJulia Montoro, MariaPomares, HelenaRamos, FernandoTormo, MarJerez, AndresNomdedeu, Josep F.De Miguel Sanchez, CarlosLeonor, ArenillasCarcel, PaulaCedena Romero, Maria TeresaXicoy, BlancaRivero, Eugeniadel Orbe Barreto, Rafael AndresDiez-Campelo, MariaBenlloch, Luis E.Crucitti, DavideValcarcel, David
- [35] Impact Of Dedicated CML Clinic On The Outcome Of Patients With Newly Diagnosed CML: Experience Of a Single Canadian CenterBLOOD, 2013, 122 (21)Damlaj, MoussabMonczak, YuryAssouline, Sarit
- [36] Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center ExperienceBLOOD, 2014, 124 (21)Baidoun, FirasChen, DongAlkhateeb, HassanZblewski, DarciElliott, MichelleHogan, William J.Litzow, MarkAl-Kali, Aref
- [37] Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experienceLEUKEMIA & LYMPHOMA, 2019, 60 (10) : 2483 - 2487Baidoun, FirasChen, DongPatnaik, MrinalGangat, NaseemaBegna, KebedeElliott, MichelleHogan, WilliamLitzow, MarkAl-Kali, Aref
- [38] CLINICIAN UTILIZATION OF THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) FOR NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTSLEUKEMIA RESEARCH, 2015, 39 : S118 - S118Pease, D.Ross, J.Poynter, J.Nguyen, P.Hirsch, B.Cioc, A.Roesler, M.Warlick, E.
- [39] IMPACT OF AZACITIDINE THERAPY ON OVERALL SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES: A POST HOC ANALYSIS OF THE ERASME STUDYHAEMATOLOGICA, 2016, 101 : 241 - 241Garcia, R.Arnan, M.Tormo, M.Calbacho, M.Coll, R.Bernal, T.Ramos, F.Marchante, I.Bastida, J. M.Albors, M.Somolinos, N.Lemes, A.Castellanos, M.Navarro, M.Lopez, S.Valcarcel, D.
- [40] IMPACT OF AZACITIDINE THERAPY ON THE SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES: A POST-HOC ANALYSIS OF THE ERASME STUDYHAEMATOLOGICA, 2016, 101 : 152 - 152Alfonso, FernandezMontserrat, ArnanMar, TormoMaria, CalbachoRosa, CollTeresa, BernalFernando, RamosInmaculada, MarchanteJose Maria, BastidaManuel, AlborsNieves, SomolinosAngelina, LemesMarta, CastellanosMireya, NavarroSilvia, LopezDavid, Valcarcel